choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Complera

Complera Newsletter
  • Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan) 31 Mar 2025 11:59 GMT

    doctor about the condition. “Despite using over-the-counter medications and prescription treatments … a medicine that contains rilpivirine (EDURANT, COMPLERA, JULUCA, ODEFSEY) used to treat HIVPharmaceuticals at 1-888-775-PHAT (7428) or FDA at 1-800-FDA

  • Gilead Sciences - Leader In HIV Medicines 14 Mar 2025 20:21 GMT

    Complera/Eviplera, Symtuza, Truvada, Stribild, and Sunlenca products for the treatmentHIV medication Biktarvy should be up 10.3%, sales of older, legacy HIV drugstrials for Lenacapavir, a biannual shot to prevent HIV … - Undiscovered Biotechnology Stock …

  • HIV Treatment Information for Pregnant Women 30 Jan 2025 20:04 GMT

    … on COMPLERA prior to pregnancy and are virologically suppressed (HIV-1 … of rilpivirine, a component of COMPLERA, were observed during pregnancy, … available for the approved treatment dose of 600 mg … available for the approved treatment dose of 600 mg …

  • 3 Biotech Stocks Revolutionizing Healthcare 30 Jan 2025 16:04 GMT

    … in fundamentally stable biotech stocks, Vertex Pharmaceuticals Incorporated (VRTX), … demand for personalized medicine and breakthroughs in … 50 novel drugs by the U.S. FDA in … Complera/ Eviplera, Stribild, Sunlencs for the treatment of HIV/AIDS, …

  • Gilead to End Free Access to Four HIV Meds Via Patient Assistance Programs 09 Jan 2025 03:02 GMT

    … Gilead’s other blockbuster HIV drugs, such as Biktarvy and … provide free medication for Truvada, Emtriva, Tybost and Complera,” stated … four medications. In addition to being used as HIV treatment, Truvada … and Descovy are daily pills, and Apretude is a …

  • STAT+: Gilead plans to halt free access to an HIV drug, worrying patient advocates 20 Dec 2024 06:52 GMT

    … no longer provide four HIV medicines for free as … the medicine — along with the HIV medicines Emtriva, Tybost, and Complera — from … not been widely reported. Pharmaceutical companies regularly tout their … them eligible for free medicine. That said, companies …

  • Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults 18 Jul 2024 12:00 GMT

    … S. Food and Drug Administration (FDA) has approved … placebo-controlled treatment period. The trial also … medicine that contains rilpivirine (EDURANT, COMPLERA, JULUCA, ODEFSEY) used to treat HIVPharmaceuticals at 1-888-775-PHAT (7428) or FDA at 1-800-FDA

  • 3 Biotechnology Stocks With Promising Pipelines 02 Nov 2024 00:15 GMT

    … strong biotech stocks Amgen Inc. (AMGN), Regeneron Pharmaceuticals, Inc … personalized medicine, and rapid acceleration in drug … , Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, … lenacapavir, the innovative HIV treatment used in combination …

  • Dexilant interactions: Alcohol, medications, and other factors 24 Oct 2024 12:53 GMT

    … “Drug interactions in depth.” Drug class or drug name Drug examples … used to treat HIV. Medications that contain rilpivirine include … Complera) Instead of Dexilant, your doctor can recommend other treatments … with supplements, foods, vaccines, or lab tests. …

  • Department of Health and Human Services Updates HIV Guidelines 09 Oct 2024 17:28 GMT

    drugs in Complera)—are no longer recommended for initial treatmentvaccination for those who test negative. The guidelines no longer recommend treatment … with HIV and a recommendation for using statins … antiretrovirals and new medications that were approved …

Satisfied with the content?

Continue to create your account.